Last reviewed · How we verify
Chronic infantile neurological, cutaneous and articular syndrome
Approved treatments
- Anakinra · Biovitrum Ab
- Kineret · Biovitrum Ab
Kineret blocks the action of interleukin-1, a protein that promotes inflammation.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Chronic infantile neurological, cutaneous and articular syndrome patent landscape — cliff calendar, originator estates, attackable patents
- Chronic infantile neurological, cutaneous and articular syndrome treatment landscape brief
- Chronic infantile neurological, cutaneous and articular syndrome treatment updates RSS
Frequently asked questions about Chronic infantile neurological, cutaneous and articular syndrome
What drugs treat Chronic infantile neurological, cutaneous and articular syndrome?
Tracked treatments include Anakinra, Kineret.
What is the treatment for Chronic infantile neurological, cutaneous and articular syndrome?
Standard treatment for Chronic infantile neurological, cutaneous and articular syndrome includes Anakinra, Kineret. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Chronic infantile neurological, cutaneous and articular syndrome patent cliff · Chronic infantile neurological, cutaneous and articular syndrome CI report
- Treatment: Anakinra · Biovitrum Ab
- Treatment: Kineret · Biovitrum Ab
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing